Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials. Scientist Satyajit Rath here simplifies the science and process involved in clinical trials of vaccines.